UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________
FORM 8-K
________________
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 19, 2003
ATHEROGENICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Georgia 0-31261 58-2108232
(State or other (Commission (I.R.S. Employer
jurisdiction File Number) Identification Number)
of incorporation)
8995 Westside Parkway
Alpharetta, GA 30004
(Address of principal executive offices)
Registrant's telephone number, including area code (678) 336-2500
_________________
Item 5. Other Events
On August 19, 2003, AtheroGenics, Inc. issued a press
release to report that the company completed the sale of
$100 million of its 4.5% Convertible Notes due 2008, which
includes the exercise by the initial purchasers of their
entire $20 million over-allotment option. A copy of the
press release is attached to this current report on Form 8-K
as Exhibit 99.1.
Item 7. Exhibits
The following exhibit is filed with this current report
on Form 8-K.
Exhibit Description
No.
99.1 - Press Release dated August 19, 2003
____________________
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, hereunto duly
authorized.
ATHEROGENICS, INC.
Date: August 19, 2003 /s/ RUSSELL M. MEDFORD
Russell M. Medford
President and Chief Executive
Officer
____________________
EXHIBIT INDEX
Exhibit Description
No.
99.1 - Press Release dated August 19, 2003